The estimated Net Worth of Brian S Posner is at least $4.91 Million dollars as of 28 October 2022. Mr. Posner owns over 2,000 units of Biogen Inc stock worth over $796,360 and over the last 18 years he sold BIIB stock worth over $3,664,119. In addition, he makes $444,643 as Independent Director at Biogen Inc.
Brian has made over 41 trades of the Biogen Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of BIIB stock worth $35,200 on 28 October 2022.
The largest trade he's ever made was exercising 25,975 units of Biogen Inc stock on 25 May 2011 worth over $1,746,819. On average, Brian trades about 1,372 units every 56 days since 2006. As of 28 October 2022 he still owns at least 4,000 units of Biogen Inc stock.
You can see the complete history of Mr. Posner stock trades at the bottom of the page.
Brian S. Posner is an Independent Director of Biogen Inc. Mr. Posner has been a private investor since March 2008 and is the founder and Managing Partner of Point Rider Group LLC, a boutique consulting and advisory services firm that provides customized solutions to senior executives and boards of financial, bio-pharmaceutical and other services-related companies, as well as strategic investors that make, direct and control investments in those sectors. From 2005 to March 2008 Mr. Posner served as the President, Chief Executive Officer and co-Chief Investment Officer of ClearBridge Advisors LLC, an asset management company and a wholly-owned subsidiary of Legg Mason. Prior to that, Mr. Posner co-founded Hygrove Partners LLC, a private investment fund, in 2000 and served as its Managing Partner for five years. He served as a portfolio manager and an analyst at Fidelity Investments, a financial services company, from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management where he also served as co-Chief Investment Officer and Director of Research. Mr. Posner also serves as a director of AQR Funds, an investment fund, and Arch Capital Group Ltd., a specialty insurance and reinsurance provider.
As the Independent Director of Biogen Inc, the total compensation of Brian Posner at Biogen Inc is $444,643. There are 11 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Brian Posner is 58, he's been the Independent Director of Biogen Inc since 2008. There are 12 older and 11 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Brian's mailing address filed with the SEC is C/O ARCH CAPITAL GROUP LTD., WATERLOO HOUSE, 100 PITTS BAY ROAD, PEMBROKE, D0, HM 08.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: